Boehringer Ingelheim’s attempt to block the Medicare Drug Price Negotiation Program was rejected by a federal judge Wednesday, handing another win to the Biden administration in the war of lawsuits challenging his signature health plan.
Chief Judge
At issue is whether the signature Inflation Reduction Act plan to lower the costs of the prescription drugs Medicare spends the most on is unconstitutional by forcing the company to agree to a maximum fair ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.